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Abstract: Most women using heroin are of reproductive age with major risks for their infants. We review clinical and ex-
perimental data on fetal, neonatal and postnatal complications associated with methadone, the current “gold standard”, and 
compare these with more recent, but limited, data on developmental effects of buprenorphine, and naltrexone. Methadone 
is a K-opioid receptor agonist and is commonly recommended for treatment of opioid dependence during pregnancy. 
However, it has undesired outcomes including neonatal abstinence syndrome (NAS). Animal studies also indicate detri-
mental effects on growth, behaviour, neuroanatomy and biochemistry, and increased perinatal mortality. Buprenorphine is 
a partial K-opioid receptor agonist and a -opioid receptor antagonist. Clinical observations suggest that buprenorphine 
during pregnancy is similar to methadone on developmental measures but is potentially superior in reducing the incidence 
and prognosis of NAS. However, small animal studies demonstrate that low doses of buprenorphine during pregnancy and 
lactation lead to changes in offspring behaviour, neuroanatomy and biochemistry. Naltrexone is a non-selective opioid re-
ceptor antagonist. Although data are limited, humans treated with oral or sustained-release implantable naltrexone suggest 
outcomes potentially superior to those with methadone or buprenorphine. However, animal studies using oral or injectable 
naltrexone have shown developmental changes following exposure during pregnancy and lactation, raising concerns about 
its use in humans. Animal studies using chronic exposure, equivalent to clinical depot formulations, are required to evalu-
ate safety. While each treatment is likely to have maternal advantages and disadvantages, studies are urgently required to 
determine which is optimal for offspring in the short and long term. 
Key Words: Methadone, buprenorphine, naltrexone, pregnancy, fetal, neonatal, offspring, development. 
1. INTRODUCTION 
  The global average prevalence of heroin abuse in 2002-4 
was 0.3%. However, there is considerable regional variation 
with, for example, an estimated prevalence of 0.1% in the 
United States, 0.2% in Africa, 0.7% in Russia, 0.8% in 
Europe, and as high as 4.4% in Iran [367]. Females make up 
a large proportion of heroin users. For example, based on 
estimates from the 2001 National Drug Strategy Household 
Survey in Australia, there are over 36,000 females (0.18% of 
the population) who use opiates either daily or weekly [277]. 
Approximately 80-90% of all women using intravenous her-
oin are of reproductive age [276, 291] and, although heroin 
can cause menstrual irregularities such as amenorrhea, oli-
gomenorrhea and suppression of ovulation [108], pregnancy 
is not uncommon [313]. Indeed, a recent study showed that 
~1/3
rd of patients presenting at a high risk clinic were posi-
tive for opioid use at some stage during their pregnancy 
[295]. In many countries, including the United States and 
Australia, oral methadone is the currently preferred mainte-
nance pharmacotherapy for the pregnant heroin user [136, 
190, 196]. However, recently, there have been a number of 
documented cases in which opioid-dependent women have 
undergone maintenance with oral naltrexone or sublingual 
buprenorphine for a portion, and in some cases the entire 
duration, of their pregnancy [158, 228, 248]. Moreover, with 
the advent of long-lasting, sustained-release naltrexone depot  
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preparations and their potential use in treating heroin and 
alcohol dependence in women, an increasing number of fe-
tuses are likely to be inadvertently exposed to naltrexone 
[149]. 
  Althoughresearch on the developmental effects of metha-
done, naltrexone or buprenorphine already exists, it is incon-
clusive as to which treatment compromises fetal and postna-
tal development the least. The primary aim of this review is 
to provide a comprehensive overview of the developmental 
outcomes from exposure to methadone, buprenorphine or 
naltrexone during pregnancy and lactation in humans. Fac-
tors in addition to direct pharmacological actions of these 
drugs are also identified. To provide further insight into the 
independent effects of these pharmacotherapies, we review 
studies using pregnant animal models with discussion on 
mechanisms involved with opioid modulation of develop-
ment. 
1.1. Role of the Opioid System in Development  
  Increasing evidence highlights the importance of the 
opioid system in mediating developmental events. Opioid 
receptor expression is regulated by signals from growth fac-
tors, proto-oncogenes and neurotransmitters [316]. Endoge-
nous opioids and receptors are also present in the developing 
mammalian fetus. For example, endorphins are found in fetal 
plasma, and the classical opioid receptors, namely mu (), 
delta () and kappa (), have been identified in the brain and 
other organs [134, 239, 360, 422, 423, 429]. Furthermore, 
opioid receptor expression [11, 229] and endogenous opioid 
concentration [11] in the fetus and neonate differ from that in 
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factor receptor or OGFr), which belongs to the nuclear re-
ceptor superfamily, is ubiquitous in the developing rat brain, 
but unlike the classical receptors, it is not found in adults 
[174, 405, 434]. In addition, exogenously administered opi-
ates such as methadone, have been localised in the brain of 
young rats, binding to -opioid receptors [299]. Moreover, 
higher methadone binding occurs in the fetal brain (2-14 
times greater) compared to maternal neurons [299]. 
  In a variety of species including mouse, rat, guinea pig 
and human, opioid levels and opioid receptor concentration 
fluctuate during development [11, 316]: universal opioid 
receptor binding is high during early embryogenesis, de-
creases towards birth, then gradually increases to adult levels 
[12, 22, 316]. Specifically, - and -receptors appear in the 
embryonic brain, whereas -receptors appear later [432] with 
a similar time course being seen in humans and rats [244]. 
Furthermore, the receptor increases are associated with in-
creases in endogenous opioid levels [11]. 
  Endogenous opioids serve as natural inhibitory trophic 
factors [405], inhibiting mitosis and DNA synthesis in the 
developing brain [293, 429]. Whilst the role of -receptors is 
not clearly understood, selective -receptor activation has 
been demonstrated to inhibit proliferation, whereas selective 
-receptor agonists inhibit neuronal differentiation [132]. 
Cell viability and death are also controlled by opioid-
mediated signalling [359], of which opioids have a tendency 
to suppress viability and increase cell death, perhaps the un-
derlying cause for smaller opioid-exposed newborns [152, 
341]. 
 The  -receptor has been shown to play a prominent role 
in the mediation of fetal cell proliferation [442], the biology 
of which has received thorough review [440]. Receptor func-
tion is regulated by its endogenous ligand, [Met
5]-enkephalin 
(opioid growth factor or OGF), which has an inhibitory ef-
fect on transcription [433]. In human and rat, it is expressed 
during development in the cerebrum and cerebellum, and in 
somatic regions, for example heart, muscle and bone [440]. 
Developmental delays observed after fetal exposure to ago-
nists, such as heroin or methadone, are postulated to result 
from their direct interaction with OGFr, retarding “normal” 
fetal development. On the other hand, fetal exposure to an 
opioid antagonist, (e.g. naltrexone) may prevent [Met
5]-
enkephalin from binding to the opioid growth factor recep-
tor, thereby blocking the growth-inhibitory effects of the 
OGF-OGFr complex [405, 435, 440, 441]; in other words, 
the brake is removed and growth is accelerated. Other stud-
ies have confirmed that OGFr localisation is associated with 
proliferating cells in the brain [174, 404, 442]. Furthermore, 
this receptor also up-regulates in response to decreased ago-
nist release and receptor binding during cell proliferation and 
growth [431]. 
2. TREATMENT FOR THE PREGNANT HEROIN 
USER 
  Heroin (diacetylmorphine) is an analogue of morphine 
which efficiently crosses the blood-brain barrier (BBB) [27] 
and its active metabolic products elicit morphine-like effects 
via agonist activity at the C-opioid receptor [309]. The abuse 
liability of intravenous heroin is attributable to its potency, 
rapid crossing of the BBB and induction of effects. The 
elimination half-life of heroin and its active metabolites is 
short (15-30 mins) [27]; tolerant users are therefore likely to 
use heroin several times each day to prevent aversive with-
drawal symptoms [168, 213]. Whilst pregnancy can be a 
powerful motivator for ceasing drug abuse, many pregnant 
women revert back to dependent heroin use, albeit com-
monly at a reduced level, and relapse post birth is common 
[104, 127, 203, 272, 295]. Heroin readily crosses the pla-
centa [232] and, consequently, maternal heroin use during 
pregnancy is associated with an increased risk for a number 
of adverse neonatal outcomes, including low birthweight, 
antepartum haemorrhage and increased neonatal mortality 
[194, 222, 237, 373, 391], many of which have been con-
firmed in animal studies [109, 223, 401, 419, 444]. Meta-
analyses on neonatal outcomes and maternal heroin use have 
produced crude odds ratios for antepartum haemorrhage 
(2.33; 95% CI 1.32-4.30) [153], low birthweight (4.61; 95% 
CI 2.78-7.65) [152] and neonatal mortality (3.27; 95% CI 
0.95-9.60) [154]. In addition, compared to non-users, women 
who continue to use heroin during pregnancy have a signifi-
cantly increased risk of exposure to infection and negative 
lifestyle factors associated with acquiring and injecting her-
oin, as well as a significantly poorer attendance at antenatal 
or other health care services [54, 222, 237].  
2.1. Methadone 
2.1.1. Pharmacology and Role of Methadone in Treatment 
of Dependence 
 Methadone  (6-dimethylamino-4,4-diphenyl-3-heptone)  is 
a synthetically derived agonist which selectively binds to the 
C-opioid receptor, thereby exerting morphine-like effects. 
Currently, methadone maintenance treatment (MMT) is the 
mostcommonlyusedpharmacotherapyforopioid-dependence 
[325]. Methadone has a high bioavailability of 40-99% [101, 
214, 260, 284, 285, 325, 330], and a relatively long elimina-
tion half-life of approximately 24 hours [164, 168, 171, 397]. 
It therefore prevents opioid-withdrawal syndrome in opioid-
dependent patients when they are maintained on a single 
dailyoral dose of 60-100 mg [56, 79, 84, 86, 168, 384] MMT 
falls within the realm of harm minimisation, and its use re-
sults in reductions in illicit drug use, crime, morbidity and 
mortality [213, 370, 385, 386, 388]. However, as methadone 
is an agonist, use of other opiates can still elicit morphine-
like effects, with fatal overdose as a potential outcome [24, 
247, 368]. For example, although sufficient methadone re-
duces or eliminates drug craving [213, 384, 393], in patients 
who fail to remain abstinent, methadone may attenuate the 
effects of, for example, heroin through cross-tolerance and 
increased competition for binding at C-opioid receptor sites 
[76, 107, 311, 384]. Another limitation with this pharma-
cotherapy is that the duration of withdrawal is protracted 
compared to withdrawal from heroin; consequently, detoxifi-
cation from methadone has lower success rates compared to 
detoxification from other opioids [4, 69, 75, 117, 118, 311].  
2.1.2. Role of Methadone in Treatment of Dependence 
During Pregnancy 
  In many countries, including Britain, the United States 
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for the pregnant heroin user. Patient compliance to MMT 
during pregnancy is generally high compared to non-pharma-
cotherapeutic interventions. Furthermore, higher methadone 
doses are associated with improved compliance, particularly 
during the last trimester of pregnancy [67, 95, 187, 220, 
356]. As MMT involves daily dispensing only by licensed 
personnel, continual contact with the patient is accomplished 
and is associated with improved antenatal care [221]. In ad-
dition, toxicological screening for illicit drugs in pregnant 
patients undergoing MMT indicate that increasing metha-
done doses are associated with decreased drug abuse [23, 
196, 251]. Thus, MMT upholds the policy of harm minimisa-
tion by reducing heroin use and other associated negative 
life-style factors, both of which improve neonatal outcomes. 
However, caution is required in selecting the maintenance 
dose for managing opioid-dependent pregnant women as 
methadone crosses the human placenta [329] and is currently 
registered by the Food and Drug Administration (FDA) in 
the United States as a Category C drug, a classification 
which is similar to that adopted by the Therapeutic Goods 
Administration (TGA) in Australia (also Category C) (Table 
1).  
2.1.3. Pharmacokinetics of Methadone During Pregnancy 
  In addition to the benefits derived from MMT, metha-
done exposure also directly affects the fetus and newborn, 
the impact of which is dictated by pharmacokinetics during 
pregnancy and the extent of transfer to offspring. Metabolic 
inactivation of methadone to its primary metabolite, 2-ethyl-
idene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in-
volves N-demethylation, mainly by hepatic cytochrome 
P4503A4 (CYP3A4) [28, 269, 325]. To a lesser extent, the 
microsomal enzymes, CYP-2D6, -1A2, -2B6, -2C9, and -
2C19 [86, 100, 111], also contribute to methadone inactiva-
tion. Furthermore, human intestinal microsomes have an 
additional metabolic role, transforming methadone sequen-
tially to EDDP and 2-ethyl-5-methy-3,3-diphenyl-pyrroline 
(EMDP) [289]. As pregnancy progresses, methadone me-
tabolism becomes enhanced, manifesting as increased clear-
ance [178, 396], with a reduced elimination half-life of 8-20 
hours compared to the 24 hour half-life in a non-pregnant 
patient [105, 306, 357]. Thus, as pregnancy progresses, lower 
methadone plasma concentrations result despite an un-
changed dose [178, 212, 306, 357, 396]. The reduction in 
methadone blood levels as pregnancy progresses may also be 
attributable to the slight increase in the volume of distribu-
tion, lowered plasma protein binding and decreased oral ab-
sorption [105, 178, 306].  
  Methadone blood levels late in pregnancy also require 
consideration. Dosing is highly variable, being 15-100 mg 
per day [43, 61, 74, 85, 112, 115, 192, 198, 246, 249, 251, 
324, 339, 398]. Methadone at 240 ng/ml or greater in the 
maternal circulation was recently identified as the required 
level for preventing maternal withdrawal during the third 
trimester, and is achieved by an oral dose of 50-150 mg [78]. 
Lower levels are associated with increased reporting of 
withdrawal symptoms which, if not addressed by the clini-
cian, can lead to patient relapse to illicit opiate use, which in 
turn is detrimental to the well-being of the individual and 
their developing offspring [78, 178, 306].  
  Drug transfer from the maternal to the fetal circulation is 
accomplished via the placenta which also acts as a barrier. 
Placental permeability is determined by the number of tissue 
layers between the fetal and maternal blood, the relative rela-
tionship of fetal to maternal blood flow, and the recruitment 
of specialised transport processes, such as facilitated and 
active diffusion. Methadone is also retained by the placenta 
and does not have adverse effects on its viability and func-
tion [281]. Furthermore, the placenta can metabolically alter 
many drugs during transfer. Methadone crosses the human 
placenta [329] and is dependent upon three processes: me-
tabolism, simple diffusion, and carrier-mediated uptake/   
efflux [274].  
  Metabolic inactivation of methadone to EDDP is medi-
ated by the placental enzyme, aromatase (CYP19) [138], but 
EMDP has not been detected in trophoblast tissue, indicating 
that sequential demethylation does not occur [275]. Placental 
metabolism allows tonic regulation of methadone transfer to 
the fetus, although inactivation by the placenta is signifi-
cantly less than that of the maternal liver or intestine [28, 
100, 275, 289]. During gestation, the placenta also undergoes 
continual structural and functional changes, which may lead 
to modulated activity and expression of metabolic enzymes. 
Whilst affinity of placental aromatase for methadone is un-
changed between 17- and 34-weeks gestation (2
nd to mid-3
rd
trimester), aromatase concentrations increase 4-fold and 
catalytic activity doubles at term (37 weeks) [138, 275], in 
part accounting for lower methadone blood levels as preg-
nancy progresses. Another factor contributing to the diffi-
culty in selecting appropriate doses is the 4- to 6-fold indi-
vidual variation in the rate of methadone metabolism by the 
placenta at term [275]. 
  Methadone transfer is also bi-directional due to dual per-
fusion of the placental lobule. The transfer and clearance 
index for methadone is greater in the returning fetal to ma-
ternal circuit compared to the maternal to fetal direction due 
to unidirectional activity of the efflux transporter, P-glyco-
protein, localised in the brush-border of trophoblast cells 
[274, 281]. 
  There have been a limited number of studies which have 
compared methadone levels in the fetus and neonate and its 
association with the period of pregnancy, maternal levels, 
and maternal dose [105]. The studies support extensive ma-
terno-fetal transfer of methadone with considerable levels in 
cord blood [281, 324], although these are approximately 5-
fold less than the maternal plasma concentration [128]. Once 
in the fetus, methadone undergoes hepatic metabolism, the 
capacity of which depends on fetal maturation, with CYP-
3A4 and -2D6 being present by week 20 [125, 219]. How-
ever, fetal metabolic capacity is considerably less than in the 
mother, due to the absence of other cytochrome enzymes, 
including CYP-2C9, -1A2 and -2B6 [125, 310]. As preg-
nancy progresses, fetal metabolic capacity increases but at 
birth decreases dramatically [250, 314, 396]. In addition, 
methadone has been identified in amniotic fluid, suggesting 
oral and cloacal uptake, although such exposure is presuma-
bly minimal compared to that received across the placenta 
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  Methadone is also transferred into breast milk, thereby 
exposing infants postnatally. The pharmacokinetic parame-
ters involved with methadone transfer into breast milk have 
been reviewed elsewhere [176, 252]. Milk-to-plasma ratios 
vary considerably between studies, ranging from 0.05 to 1.89 
[25, 212]. With an average breast milk intake of 475 ml/day 
and a large maternal dose range (10-180 mg/day), the esti-
mated neonatal/infant intake of methadone via the breast 
milk ranges widely (0.01-0.1 mg/day). [25, 110, 212, 252]. 
The elimination half-life in neonates is longer (32.5 h) than 
in adults (24 h) [212], contributing to higher levels on a mg 
per kg basis [105, 281, 324]. Nevertheless, the relative infant 
dose has been estimated as 2.8% of the maternal one [16]. 
Despite the relatively low level of infant exposure to metha-
done, caution is required for lactating women undergoing 
MMT as animal studies have demonstrated altered postnatal 
development [256, 257, 409-411, 418, 420].  
2.1.4. Methadone and Developmental Effects 
2.1.4.1. Methadone and Fetal Outcomes
  Methadone has undoubtedly improved the management 
of pregnancy and neonatal outcome in heroin addicts [196]. 
For example, high methadone doses in the third trimester are 
related to improved fetal growth compared to pregnancies of 
non-treated heroin addicts [124]. Importantly, no serious 
fetal toxicity has been associated with methadone [81, 222]. 
However, human studies have identified adverse effects as-
sociated with methadone use during pregnancy, although 
many of these findings are inconsistent and have not estab-
lished a causal link to methadone use. Poor outcomes include 
a higher incidence of prematurity [6, 85, 324], intrauterine 
growth retardation [6, 74, 195, 198, 324] and increased fetal 
mortality [198, 242]. Clinical observations in utero have also 
shown that fetal activity, respiration and heart rate are de-
pressed in mothers taking daily oral methadone compared to 
those not dependent on opioids [175, 307, 398].  
2.1.4.2. Methadone and Neonatal Outcomes
  Methadone maintenance treatment in the stabilised pa-
tient, when combined with antenatal care and supervision of 
illicit drugs, produces a considerable improvement in birth-
weight and decreases the risk of neonatal morbidity, when 
compared to the outcomes of neonates from non-treated 
pregnant heroin users [88, 196, 198, 350, 373]. However, 
MMT during pregnancy is still associated with poorer neona-
tal outcome compared to drug-free controls. For example, 
the proportion of infants of low birthweight ranges from 29-
62% (mean: 45%; n=730) for heroin [88, 102, 312, 350, 351, 
443], 18-47% (mean: 29%; n=845) for methadone [88, 129, 
180, 283, 350, 443], and 3-15% (mean: 15%; n=42019) for 
drug-free controls [88, 102, 129, 180, 351]; these studies, 
however, did not consistently control for confounding fac-
tors, such as other drug use. Additionally, when compared to 
drug-free controls, MMT during pregnancy is associated 
with reduced head circumference [33, 74, 231] as well as 
slight increases in neonatal mortality [54, 154, 194], morbid-
ity and the incidence of neonatal abstinence syndrome [6, 61, 
80, 129, 191, 324].  
  In comparison to low dose MMT, birthweight and head 
circumference is improved by higher methadone dosing dur-
ing the early and late phases of pregnancy [74, 124, 195]. 
Such improvements in neonates are presumed to be a conse-
quence of better lifestyle factors (e.g. nutritional intake) and 
reduced drug abuse. Indeed, human studies using lower 
methadone doses, which were insufficient to alleviate with-
drawal symptoms, were associated with increased abuse of 
other drugs [23, 196, 251]. Furthermore, a recent investiga-
tion on human development following in utero exposure to 
methadone demonstrated dose-related growth effects con-
trary to that previously reported, whereby, neonates from 
patients administered methadone during pregnancy for the 
management of opioid-dependence were compared with 
newborns of patients who received methadone for the man-
agement of pain [339]. The dosing regimens differed in that 
patients being managed for pain received lower doses of 
methadone (40 mg/day) and for a shorter duration of time (5 
weeks toward end of pregnancy) in comparison to heroin 
users undergoing MMT, who received 60 mg per day for a 
duration of 36 weeks [339]. As pain-managed patients were 
not opioid-dependent prior to receiving methadone, they 
were less likely to use other drugs of abuse than the cohort of 
opioid-dependent patients, when methadone reached trough 
levels. This effect is in part due to their lower levels of toler-
ance from an abstinent history of opioid use. Thus, it may be 
proposed that these data reflect the true pharmacological 
actions of methadone, whereby higher doses are associated 
with a greater suppressant effect on growth. 
2.1.4.2.1. Methadone and Neonatal Abstinence Syndrome
  Neonatal abstinence syndrome (NAS) is characterised by 
high-pitched crying, hyperactive reflexes, tremors, hyper-
tonicity, convulsions, frantic suckling of fists, poor feeding, 
regurgitation, diarrhoea, dehydration, yawning, sneezing, 
nasal stuffiness, sweating, skin mottling, fever, rapid respira-
tion and skin abrasion, as assessed by the Finnegan scale [91, 
128, 191, 194, 324]. Although symptoms can lead to pro-
longed hospital stays for the new born [183], behavioural 
abnormalities do not persist. However, withdrawal following 
MMT is likely to be more prolonged than that from heroin 
[177] and, if NAS is left untreated, there is an increased risk 
of mortality [88, 304]. Consequently, some physicians are 
reluctant to increase the daily methadone dose as pregnancy 
progresses, despite the increased clearance and volume of 
distribution and, therefore, reduced plasma concentrations 
and declining patient satiety. Moreover, some highly moti-
vated patients are encouraged to endure gradual dose reduc-
tions to accomplish complete detoxification prior to parturi-
tion [60, 215, 246, 294]. However, this approach is generally 
avoided as the post-detoxification risk of relapse [92] is 
likely to involve fluctuating opiate levels, leading to numer-
ous complications, such as fetal distress, meconium aspira-
tion, fetal hypoxia and death [90, 177, 190, 447]. As NAS 
can be managed pharmacologically, stabilisation onto 
methadone, involving sufficient dosing and employment for 
the duration of gestation, is the preferred management for the 
pregnant opioid-dependent woman [190, 191, 294]. 
  The incidence of NAS when pregnant opioid-dependent 
women receive MMT is typically 60-90% of newborns [33, 
129, 189, 194, 228, 324]; a large proportion of which (45-
80%) endure severe withdrawal, necessitating pharma-
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80, 195, 246, 339]. The issue of maternal methadone dose 
versus the prognosis of NAS remain unresolved; whilst a 
number of studies show a positive correlation between dose 
and the prevalence, duration and severity of NAS [61, 73, 
246, 294, 339], others report the absence of this association 
[23, 33, 194, 243, 283, 324]. The inconsistency is presuma-
bly from the inability to appropriately control for numerous 
confounding factors, such as poor antenatal care, smoking, 
poverty, personal neglect, and poor health status [364]. For 
example, a recent study demonstrated that the onset and se-
verity of NAS was greater in neonates from patients smoking 
more than 20 cigarettes per day versus less than 10 per day 
[46]. Other studies do not sufficiently control for cigarette 
smoking [1, 129, 246, 249], or other drugs which can influ-
ence the prognosis of NAS [112, 191, 339]. Another study 
showed that higher methadone doses in third trimester were 
associated with increased gestational age, and after adjust-
ments were made for maternal dose and gestational age, a 
correlation was found between NAS, gestational age and 
race, with non-black infants exhibiting higher NAS scores 
than black infants [124].  
  The rate of decline in neonatal methadone plasma con-
centration is positively correlated with the severity of NAS 
during the first four days after birth [73]. Another study 
which examined neonatal plasma concentration and NAS 
reported that neonatal withdrawal was not observed if their 
methadone plasma concentration was greater than 60 ng/ml 
[324]. This finding is consistent with recent data whereby 
maternal withdrawal is avoided when methadone plasma 
levels are greater than 240 ng/ml [78]. Indeed, it has been 
shown that maternal and fetal withdrawal occur simultane-
ously [2], even though perinatal methadone blood levels are 
approximately 5-fold less than maternal ones [128]. The 
findings provide a plausible explanation for observed de-
creases in the severity of NAS after exposing the newborn to 
methadone  via the breast milk [1, 9, 245, 252]. This ap-
proach may therefore be useful in the management of the 
newborn displaying symptoms of withdrawal. 
  Improved management of the pregnant opioid-dependent 
person may be achieved by MMT with split dosing, whereby 
half the standard methadone dose is administered twice-daily 
[196, 252, 357]. Compared to single-daily dosing, split-
dosing more closely resembles a steady state plasma concen-
trations over a 24 hour period [395]. Furthermore, metha-
done is sustained at a higher concentration and for longer 
from a split rather than a once-daily dose [110, 196, 357]. In 
addition, compared to single-dosing, split-dosing during the 
third trimester of pregnancy is associated with reduced co-
caine abuse and improved compliance [67]. It is therefore 
suggested that split-dosing will improve compliance and 
treatment by producing fewer withdrawal symptoms [357], 
reducing depression of fetal body movements and breathing 
rate [175]. However, there have only been a few investiga-
tions into the benefits of split-dosing during pregnancy; al-
though, based on these preliminary findings, further studies 
are warranted. 
2.1.4.3. Methadone and Postnatal Outcomes
  Postnatal effects from MMT exposure during pregnancy 
include reduced postnatal weight gain, head circumference 
and height [42, 127, 346, 353, 365]. However, although opi-
ate-induced growth reductions have a tendency to diminish 
with age [226, 231, 446], they can persist for up to 5.5 years 
[369].A weak association has also been made between MMT 
and sudden infant death syndrome, although a causal effect 
is yet to be established [89, 142, 197, 304]. Other postnatal 
effects include an increase in the incidence of mortality [33, 
221, 346], microcephaly [6], strabismus [112] and behav-
ioural effects such as mood, attention and cognitive deficits 
[13, 43, 115]; behavioural outcomes following prenatal ex-
posure to opiates have previously been reviewed [193]. It 
was recently shown that at four months of age, a highly sig-
nificant difference in neurological development exists be-
tween control infants, and infants exposed to methadone 
during the prenatal period, with methadone-exposed infants 
displaying a 14% greater latency in reaching peak visual 
evoked potentials (VEPs), in response to changing patterned 
visual cues [392]. Infants of mothers who underwent MMT 
during pregnancy display higher scores for disorganised and 
avoidant behaviour, as well as lower scores of contact-
maintaining behaviour at 12 months of age [115, 127]. Fur-
thermore,infantsofdrug-dependentmothers receiving metha-
done had delayed cognitive development, persisting in up to 
50% of these infants until 5 years of age [369]. These infants 
are also less interactive at 5 years of age compared to the 
normalpopulation.Inaddition,7 year old methadone-exposed 
infants differed from controls in their behaviour at school, 
displaying poorer achievement, increased aggression and 
school disruptions [323]. However, other reports found no 
difference between methadone-exposed, heroin-exposed and 
control infants aged 3 to 5 years with respect to cognitive 
and social function [115, 127, 192, 231, 352].  
2.1.5. Concomitant Heroin Use During Methadone Main-
tenance Treatment 
  Although heroin-using women who stabilise on metha-
done at or around the time of conception show good progno-
sis, those who fail to stabilise and continue regular heroin 
use throughout pregnancy show significantly poorer progno-
sis [152-154]. For example, a meta-analysis of neonatal 
birthweight showed a lower relative risk estimate for women 
stabilised on methadone at or near the time of conception 
(RR 1.36; 95% CI 0.83-2.22) compared to those who failed 
to stabilise and continued to use heroin (RR 3.28; 95% CI 
2.47-4.39) [154]. Despite improvements over those continu-
ing to use heroin, neonatal outcomes such as birthweight and 
delivery at term for those on MMT are significantly poorer 
than for matched controls who do not use heroin [152, 155]. 
Furthermore, neonates/infants of those treated with metha-
done who also co-use illicit opiates are at increased risk of 
death [154]. Similarly, there is an increased likelihood of 
infants developing NAS when mothers undergoing MMT 
supplement with heroin [61].  
  There are major improvements associated with MMT in 
the risk of exposure to infection, negative lifestyle factors, 
reduction of heroin use, antenatal attendance and neonatal 
outcomes such as antepartum haemorrhage, low birthweight 
and neonatal mortality [139, 152-154, 194, 221]. However, 
there are adverse effects associated with MMT during preg-
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treatments. The critical issue in improving outcomes for 
opioid-dependent pregnant women is either achieving a sta-
ble intra-uterine milieu, with minimal intoxication and with-
drawal, or minimising exposure to opioids and the associated 
potential growth-suppressive effects. Clinical evidence sug-
gests greater benefit from the former. Whilst abstinence from 
any drug is ideal during pregnancy, detoxification from 
MMT might not be ideal if the consequences include a rever-
sion to illicit opiate or other drug use. Although detoxifica-
tion from methadone before parturition can be accomplished 
in highly motivated patients [60, 155], continued illicit drug 
use is likely and the high level of maternal complications 
suggests that improvements are needed in the treatment of 
pregnant heroin users [198]. 
2.2. Buprenorphine 
2.2.1. Pharmacology and Role of Buprenorphine in Treat-
ment of Dependence 
 Buprenorphine  ([9-cyclopropylmethyl-4,5-epoxy-6,14-
ethanomorphinan-7-yl]-3-hydroxy-6-methoxy-3,3-dimethyl-
butan-2-ol) is a semi-synthetic thebaine derivative which 
selectively binds as a partial agonist to the E-opioid receptor, 
and to the -opioid receptor as an antagonist [225, 230, 280], 
although the latter role is unclear as a more recent study im-
plicates agonistic activity at the -opioid receptor in relation 
to analgesia [303]. Buprenorphine was first evaluated for its 
potential in maintaining the opioid-dependent person in 1978 
[179], although it was not approved by the United States 
legislature until 2000, and by the FDA until 2002 [98]. As a 
partial agonist, buprenorphine potently induces morphine-
like effects at a relatively low-dose, but at higher doses, it
has a submaximal response compared to full agonists, such 
as morphine and heroin, and begins to attenuate in its agonis-
tic effect [230, 308]. Buprenorphine also attenuates the ef-
fects of other opioid agonists, through increased competition
for binding at the  E-opioid receptor [355]. Sublingual bu-
prenorphine is rapidly absorbed and distributed, with a 
bioavailability of approximately 50% (range: 16-94%), 
which is marginally less than the bioavailability of metha-
done [36, 52]. However, it slowly dissociates from the opioid 
receptor binding sites resulting in a biphasic elimination 
half-life of approximately 30 hours with an initial rapid 
phase of 3 to 5 hours, followed by a slow phase greater than 
24 hours [35, 36, 52, 216].  
  Buprenorphine is a highly lipophilic agent which is ex-
tensively metabolised in the liver by N-dealkylation to nor-
buprenorphine; similar to methadone, the process is mainly 
(~75%) mediated through CYP3A4 [53, 172, 205], with the 
remaining ~25% mediated by CYP-3A5, -3A7 and -2C8 
[172, 205, 270]. The active metabolite, norbuprenorphine, 
along with its parent compound, undergo inactivation by 
conjugation with glucuronic acid [53, 290]. 
  The regimen commonly employed clinically is daily sub-
lingual administration (Subutex®) [30, 363]; buprenor-
phine’s efficacy has been reviewed elsewhere [62, 207, 235, 
236]. Buprenorphine doses used to manage the opioid-
dependent person vary considerably (mean dose range: 1-24 
mg/day) [184, 208, 234, 355, 363]. In comparison to lower 
doses (1-4 mg/day), the typical dose range of 8-16 mg/day is 
associated with improvements in patient compliance and 
abstinence from other opioids [236, 332, 333, 355]. How-
ever, its effect in reducing abuse of non-opioid drugs, such 
as cocaine, is less pronounced [119, 333, 389]. Further bene-
fit of buprenorphine for managing addiction resides in its 
partial agonist properties since reduced liability for abuse, 
accidental overdose and adverse effects are attributed to bu-
prenorphine’s ceiling effect, whereby higher doses are asso-
ciated with much smaller increases in morphine-like effects 
[10, 30, 230, 236]. In addition, withdrawal is generally well 
tolerated, being less severe than for heroin or methadone 
[114, 238, 355]. Despite its advantages, buprenorphine car-
ries the potential for abuse [30]. However, the Suboxone® 
formulation prevents abuse since buprenorphine is combined 
with the short acting E-opioid receptor antagonist, naloxone 
[3].Whentakensublingually,the poor bioavailability of nalo-
xone (<10%) results in minimal interference with systemic 
buprenorphine; however, if taken intravenously, naloxone 
blocks the pleasurable effects of buprenorphine [97, 130, 
259].  
2.2.2. Role of Buprenorphine in Treatment of Dependence 
During Pregnancy 
  The benefits of buprenorphine maintenance of the non-
pregnant heroin user are also seen in pregnancy [286], with 
retention to treatment, reduced illicit drug use, and improved 
safety with regards to overdose [185, 188, 189]. The TGA 
and FDA have classified buprenorphine into the same preg-
nancy category (C) as methadone [38] (Table 1), although, 
its use as a maintenance treatment during pregnancy is re-
stricted due to a lack of data. Nevertheless, human studies 
have been conducted where FDA restrictions do not apply, 
including France, Belgium and Austria. In France, buprenor-
phine has been used as a standard treatment for opioid-
dependence for over a decade. Whilst some women contin-
ued buprenorphine maintenance after conceiving, others un-
derwent detoxification from heroin, followed by induction 
onto buprenorphine [5, 228, 286]. Buprenorphine doses used 
to maintain the pregnant woman are variable, with a mean 
dose range of 5.3-18.7 mg/day [93-95, 186, 189, 218, 228, 
331]. Similar to methadone, buprenorphine is transferred 
across the placenta to the neonate [273], although this occurs 
to a lesser extent, presumably due to buprenorphine’s greater 
molecular weight (504.1 Da). 
2.2.3. Pharmacokinetics of Buprenorphine During Preg-
nancy 
  Also in parallel with methadone, buprenorphine is me-
tabolised by the placenta [70, 273]. Transfer of buprenor-
phine and norbuprenorphine across the placenta is evidenced 
by its detection in umbilical cord and neonatal blood, urine 
and meconium, with cord levels ranging 101-137 ng/ml 
[186, 248]. The placenta can also accumulate buprenorphine, 
thereby acting as a depot and allowing slow dissociation to 
the fetus [273]. Nonetheless, placental metabolism, mediated 
via the placental enzyme aromatase (CYP19), reduces the 
amount of transferred [70, 273]. A further reduction in fetal 
exposure is mediated by the efflux transporter molecule P-
glycoprotein [282]. There are low levels of CYP3A4 in fetal 
liver and so fetal metabolism does occur, although this is 
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ated through CYP3A7 [125, 400] which would account for 
the higher neonatal plasma levels at term compared to ma-
ternal trough levels [248]. During lactation, buprenorphine is 
transferred via breast milk at a similar concentration to that 
found in maternal plasma (0.230 to 0.720 ng/ml) but this 
level of neonatal exposure is considered to be negligible 
[186, 248].  
2.2.4. Buprenorphine and Developmental Effects 
2.2.4.1. Buprenorphine and Offspring Outcomes
  Clinical retrospective and prospective studies on bu-
prenorphine maintenance for pregnant opioid-dependent 
women indicate that it is a well tolerated and safe [93, 185, 
188, 228]. Neonatal outcomes are not conclusive as studies 
are limited [93, 186, 228]. Nevertheless, most pregnancies 
lack complications with neonatal outcomes, including birth-
weight,APGAR scores, head circumference and body length, 
being within normal ranges [93, 94, 331]. In addition, mor-
tality is not a major problem, with one stillbirth and one 
spontaneous abortion being the only reported cases [218]. 
Notwithstanding the benefits of managing pregnant opioid-
dependent women with buprenorphine, caution is needed as 
adverse effects have been associated with this treatment. For 
example, one study reported that 10% of buprenorphine-
exposed newborns (of 259) were delivered prematurely, 
compared to a normal incidence of 7% [228]. Furthermore, 
another study reported that 5.8% (2/34) newborns had mal-
formations [218]. Follow-up postnatal studies are also 
scarce, although in a recent study, neurological development 
of infants exposed to buprenorphine during gestation was 
shown not to differ from control infants at four months, as 
assessed by measurement of VEP latencies [392]. It is of 
concern that lower limb hypertonia, jerky movements and 
jitteriness in some newborns have been reported to last for 3-
9 months [201], although these may be a consequence of 
maternal poly drug use during pregnancy and/or lactation 
[126, 377, 378]. 
2.2.4.2. Buprenorphine and Neonatal Abstinence Syn-
drome
  Neonatal abstinence syndrome is apparent in only a few 
buprenorphine-exposed newborns, a feature considered to be 
a major advantage of this drug treatment during pregnancy, 
[94, 185, 218]. However, one study of 13 neonates reported a 
NAS incidence rate of 85% [201]. Nonetheless, in most 
cases, NAS presented as mild and did not require treatment 
[94, 185, 218]. This may, at least in part, be explained by the 
extensive metabolism of buprenorphine within, and rela-
tively low transfer across, the placenta. Symptoms appear at 
12 hours, peak at around 72 hours and alleviate at 120 hours 
after the last buprenorphine dose [95, 186], although this 
timing could be confounded by the use of other drugs, such 
as tobacco [46]. Plasma levels above 0.7 ng/ml reportedly 
prevent withdrawal [217]. There are currently no evidence-
based guidelines for breastfeeding in women maintained on 
buprenorphine during pregnancy and breast feeding due to 
lack of conclusive data [94, 185, 228, 248]. However, breast-
feeding occurs and buprenorphine, regardless of maternal 
dose, does not alter the effectiveness of using morphine to 
treating NAS [116, 186].  
2.2.5. Sublingual Buprenorphine Versus Methadone Main-
tenance 
  A number of investigations have made comparisons be-
tween neonatal outcomes from buprenorphine or methadone 
maintenance during pregnancy. A buprenorphine dose of 8 
mg/kg is comparable to a methadone dose of 60 mg/day with 
respect to efficacy in treating addiction and reducing drug 
abuse [236]. MMT is associated with lowered use of addi-
tional opioids, as indicated by random toxicological screen-
ing, whereas buprenorphine is associated with greater patient 
compliance [95, 389]. Whilst buprenorphine is less toxic to 
the fetus than methadone [288], the increased use of other 
drugs during the buprenorphine-maintained pregnancy may 
produce worse outcomes for the neonate [82, 126, 151].  
  In general, however, management with buprenorphine 
during pregnancy is comparable to MMT, with regards to 
safety of the neonate. In 2006, a study with 259 participants 
did not identify any major differences for perinatal outcome 
between methadone (57+/-30.4 mg) and buprenorphine (5.4 
+/- 4.5 mg) [228]. However, the peak NAS severity was ob-
served earlier in newborns exposed to buprenorphine during 
gestation, compared to newborns exposed to methadone (66 
versus 81 h) [228]. Conversely, the onset of NAS was earlier 
Table 1.  Overview of FDA (United States) and TGA (Australia) Pregnancy Classification Relevant to Methadone, Buprenorphine 
and Naltrexone 
  Category Definition  Drug(s) in Category 
FDA (United 
States) 
C: ‘‘….either studies in animals have revealed adverse effects on the fetus (teratogenic or embryo-
cidal effects or other) and there are no controlled studies in women, or studies in women and ani-
mals are not available.” 
Methadone, Buprenorphine, 
Naltrexone 
B3: “Drugs which have been taken by only a limited number of pregnant women and women of 
childbearing age without an increase in the frequency of malformation or other direct or indirect 
harmful effects on the human fetus having been observed. Studies in animals have shown evidence 
of an increased occurrence of fetal damage, the significance of which is considered uncertain in 
humans.” 
Naltrexone 
TGA (Australia)
C: “Drugs which, owing to their pharmacological effects, have caused or may be suspected of caus-
ing harmful effects on the human fetus or neonate without causing malformations. These effects 
may be reversible. Accompanying texts should be consulted for further details.” 
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following MMT (60 h) compared with buprenorphine (72 h) 
[95], which may be explained by the longer terminal half-life 
of buprenorphine [35, 36, 52, 216]. Furthermore, NAS is 
generally more severe following MMT [228], as indicated by 
a higher amount of morphine required to treat NAS in com-
parison to the amount required for treating buprenorphine-
exposed infants [189]. Reduced NAS in buprenorphine ex-
posed infants may be due to decreased placental transport. 
As discussed earlier, VEP latencies of infants exposed to 
methadone were significantly longer than control infants, 
whereas maternal use of buprenorphine during pregnancy 
resulted in infant VEPs similar to controls, conferring an 
advantage over methadone [392].  
2.3. Naltrexone 
2.3.1. Pharmacology and Role of Naltrexone in Treatment 
of Dependence 
  Naltrexone (N-cyclopropylmethyl-noroxymorphone) is a 
thebaine-derivative that binds non-selectively to opioid re-
ceptors as an antagonist, its pharmacological action in block-
ing the effects of opioids (such as methadone, morphine and 
heroin) may be useful to prevent relapse in opioid-dependent 
patients [113, 120]. Systemic naltrexone efficiently crosses 
the human blood-brain barrier [96, 199, 227, 267]. Com-
pared to other antagonists (such as nalorphine and naloxone), 
naltrexone has a long duration of action (elimination half-
life: ~4 hours) and greater antagonist potency [380, 402]. 
Naltrexone is principally eliminated by the liver, where 
metabolic (NADPH-dependent) reduction of its 6-keto group 
produces 6,-naltrexol [26, 266, 381]. Additional hepatic 
metabolism is mediated by glucuronic acid conjugation and 
catechol-O-methyl transferases, resulting in the formation of 
a number of minor metabolites which are excreted primarily 
by the kidney [40, 266, 375, 380-382]. In humans, plasma 
naltrexone concentrations are 10 times less than that of its 
primary metabolite, 6,-naltrexol [40] which has about a 
1/100 the antagonistic potency of naltrexone at the I-opioid 
receptor [39, 170]. The ability of naltrexone to effectively 
antagonise heroin use has been clearly established, but the 
exact level required is still in question. It has been shown 
that serum naltrexone blood levels of 2.8 ng/ml block 500 
mg of snorted pure pharmaceutical diacetylmorphine [32], 
2ng/ml blocks the effects of 25 mg of intravenously admin-
istered heroin [279, 376] and 1 ng/ml antagonises 15 mg 
morphine [45]. The generally cited therapeutic blood level 
for the management of heroin dependence is 2 ng/ml [32, 50, 
156, 264], which is 87% effective in blocking the effects of 
25 mg intravenously administered heroin [51], although 
higher values may be needed to provide 100% coverage. 
Notwithstanding the poor oral bioavailability (40%) of 
naltrexone, it has been available for many years as an oral 
formulation (ReVia®), commonly involving daily self-
administration (50 mg) to maintain therapeutic blood levels, 
although other prescribing patterns, such as 100 mg three 
times per week are also used [264]. The standard oral dose of 
one 50 mg tablet per day produces a peak of ~8 ng/ml of 
blood naltrexone, decaying to 1.1 ng/ml within 24 hours 
[380]. However, oral naltrexone is associated with poor 
compliance [21, 328]. 
  An alternative to oral naltrexone involves either injection 
of a depot formulation or surgical insertion of a sustained-
release implant. Either approach removes the onus on pa-
tients to use oral naltrexone on a daily basis. Several sus-
tained-release naltrexone implants have been developed 
which maintain therapeutic blood levels (>2 ng/ml) for 4-8 
weeks [29, 32, 49, 209, 263, 362]. Depotrex® (192 or 384 
mg naltrexone) is an injectable depot formulation which an-
tagonises the effects of intravenously-administered heroin 
(0-25 mg) for 3-5 weeks, and is safe and well tolerated in 
opioid abusers, supporting its use as a treatment for opioid 
dependence [50]. Similarly, Vivitrol® (formally known as 
Vivitrex) is an injectable depot formulation which produces 
peak naltrexone plasma levels within 3 days, dropping to an 
undetectable level (<1 ng/ml) by 35 days [15]. Preliminary 
data indicate that in humans, intramuscular Vivitrol is also 
well tolerated with reported adverse effects being mild to 
moderate [106].  
  However, although sustained-release injectable and im-
plantable preparations help overcome the issue of daily 
medication and non-compliance, they only last for short pe-
riods and still incur significant levels of non-compliance. For 
example, in an 8-week Depotrex trial, with re-treatment at 4 
weeks, 32% of the high dose and 40% of the low dose par-
ticipants dropped out of the study [51]. Extrapolating from 
pharmacokinetic data derived from those with alcohol de-
pendence, re-treatment of those with opioid dependence with 
injectable naltrexone would be required on a monthly basis 
[106, 210]. Therefore, although these newer sustained-
release preparations help to overcome the issue of non-
compliance for short periods (typically 21-28 days), they still 
incur significant levels of attrition with patients required to 
return every 3-4 weeks for re-treatment. Longer lasting sus-
tained-release preparations might offer advantages for indi-
vidual patients and the community. 
  An implantable naltrexone formula (GoMedical Indus-
tries Pty Ltd) has been used under the Commonwealth 
Therapeutic Goods Administration Special Access Scheme 
(“Compassionate Guidelines”) in Western Australia since 
August 2000. GoMedical implants in humans maintain 
naltrexone at therapeutic levels, i.e. above 2 ng/ml, for ap-
proximately 5.5 months, and 1 ng/ml for 9 months [147-
149], and are associated with a significant reduction in hos-
pital presentations and accidental overdose [159, 160]. How-
ever, there is concern regarding an increased risk of acciden-
tal overdose if relapse to opioids were to follow maintenance 
treatment with naltrexone [58, 265, 315, 336, 349, 370].  
  Fatal and non-fatal overdoses may be prevalent with 
naltrexone because, being an antagonist, it reduces tolerance 
to opioids; in addition, chronic exposure may result in up-
regulation of opioid receptors thereby increasing sensitivity 
[72, 390]. Increased risk of mortality due to reduced toler-
ance has been shown in humans following periods of absti-
nence, such as following incarceration [58] but, although 
receptor up-regulation has been demonstrated in animal 
models [361, 403], it is still unclear if it occurs in humans [7, 
55, 390]. Furthermore, naltrexone has been shown to sup-
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physiological effects [334, 376]. This dichotomy may in-
crease the chance of an overdose as the user does not receive 
the expected level of feedback from a given level of opioid 
use, but still experiences physiological effects such as respi-
ratory depression [72].  
2.3.2. Role of Naltrexone in Treatment of Dependence 
During Pregnancy
  Naltrexone is not recommended for use during pregnancy 
due to lack of data on prenatal exposure and in Australia is 
classified as a B3 drug (Table 1) – one where “…studies in 
animals have shown evidence of an increased occurrence of 
fetal damage, the significance of which is considered uncer-
tain in humans” [38]. The FDA classifies naltrexone in the 
same category (C) as methadone and buprenorphine (Table 
1). However, because termination of maintenance therapies 
may be associated with relapse to heroin use, some pregnant 
women elect to remain on oral naltrexone during at least 
part, and some for the entirety, of their pregnancies [158]. 
One potential reason for remaining on naltrexone is that its 
lack of agonist activity circumvents neonatal abstinence syn-
drome [191, 427]. Detoxification of pregnant women onto 
oral or implanted naltrexone maintenance has also occurred 
in 6 cases, when these patients were unable to stabilise onto 
other maintenance treatments [146, 156-158]. The efficacy 
of naltrexone for treatment of the opioid-dependent pregnant 
woman has not sufficiently been assessed; the limited studies 
did not comment on toxicological screening for substance 
abuse. 
2.3.3. Pharmacokinetics of Naltrexone During Pregnancy 
  Whilst transfer of naltrexone into breast milk has been 
shown in sheep and humans [39, 40], and placental transfer 
demonstrated in rat [406, 407], naltrexone transfer across the 
human placenta has not been reported. Indeed, transfer of 
both naltrexone and 6,-naltrexol may be limited by their 
extensive conjugation with glucuronic acid thereby reducing 
their permeability [71, 211, 326, 380, 382]. However, conju-
gated naltrexone and 6,-naltrexol may be transferred by 
some as yet unknown transport mechanism. Nevertheless 
unconjugated transfer presumably does occur in humans, as 
occurs for many other drugs [292, 371, 387]. A single case 
study confirmed that maternal naltrexone levels can be sus-
tained above a therapeutically effective threshold of 2 ng/ml 
for at least the first 214 days of pregnancy, reflecting similar 
levels measured in non-pregnant patients [147-149]. Placen-
tal transfer of naltrexone occurs in rat [406, 407], and despite 
interspecies difference in placental morphology, transport 
and metabolism is functionally similar [262, 358]. Indeed, 
opioidergic drugs, including morphine and naloxone, which 
are very similar to naltrexone [26, 44], rapidly cross the hu-
man placenta and enter the fetal circulation [47, 57, 206]. 
Furthermore, the physiochemical properties of naltrexone, 
namely its alkalinity (pKa: 8.13), high lipid solubility (octa-
nol/water distribution: 13.08) [200], small molecular weight 
(341.41 Da) [182], and low plasma protein binding of 21-8% 
[68, 241] are factors which facilitate placental transfer [71, 
140, 296, 354]. In contrast, 6,-naltrexol, is hydrophilic 
[374] and its placental transfer is likely to be minimal com-
pared to naltrexone. Transfer of naltrexone and 6,-naltrexol 
in human lactate is low with an estimated total relative infant 
dose of 1.06% in a 24 hour period. Moreover, whilst 1.1 
ng/ml 6,-naltrexol was detected in neonatal plasma, no 
naltrexone was identified [40]. 
2.3.4. Naltrexone and Neonatal Outcomes 
  Few data are available on the impact of oral or implant-
able naltrexone exposure and feto-maternal complications in 
pregnant humans [146, 149, 156-158]. Whilst all were co-
authored by one of the contributors to this review (GKH), 
they include data from Australia, United Kingdom and Por-
tugal and are the only publications on maternal and neonatal 
outcomes in humans following naltrexone exposure during 
pregnancy. Australian cases were treated through the Austra-
lian Medical Procedures Research Foundation (AMPRF): 
until August 1999, oral naltrexone was only available in 
Western Australia (WA) from AMPRF. Clinic records indi-
cate that 1196 patients had oral naltrexone maintenance be-
tween June 1997 and August 1999. A review of the first 300 
patients indicated that 136 (45.3%) were females of repro-
ductive age [150]. 
  To January 2006, treatment files (AMPRF) indicated that 
46 pregnant women treated with oral naltrexone had main-
tained contact with the clinic at time of birth (GKH, personal 
communication). Data on 10 cases treated with oral naltrex-
one in Australia, Portugal and United Kingdom indicate that 
outcomes of the seven births delivered at the time of study 
were generally unremarkable in terms of gestation age (be-
tween 38-40 weeks), good birth weight, head circumference, 
and APGAR scores. This was with the exception of one case 
in which the baby was induced at 36 weeks (resulting in low 
birth weight) due to maternal hypertension, and one other 
case of a baby weighing 2626 g at birth, born to a mother 
under 40 kg before conception and a father under 50 kg. Pe-
riodic foetal monitoring of the remaining three cases at the 
time showed normal development [158]. As the authors ad-
mit, the data may be biased since it only involved patients 
who maintained contact with the clinic, a factor which is 
known to improve outcome [221, 228]. No post-birth follow-
up has taken place on any infants exposed during pregnancy. 
There is no indication as to the outcome in those who failed 
to maintain contact. 
  To January 2006 in Western Australia, approximately 
650 women of reproductive age, had undergone treatment 
with the GoMedical naltrexone implant and, of these, 43 
pregnant women were in contact with the drug treatment 
clinic at the time of birth (GKH, personal communication). 
Similar to oral naltrexone, review of the first nine neonatal 
cases with exposure at different stages of pregnancy for dif-
ferent patients indicate that neonatal and obstetric outcome 
was unremarkable. Some statistics of interest were: half (4) 
of the case babies were delivered via spontaneous vaginal 
delivery, gestation age ranging between 37.5 and 41 weeks, 
birth weight between 2720 g and 3845 g, length 47-53cm, 
head circumference 31-35.3 cm, and 5-minute APGAR 
scores of at least 9 [146, 156]. Again, these cases may be 
biased to more positive outcomes in patients who maintained 
contact with the drug treatment service. Taken together, the 
reports suggest no adverse effects on neonates from naltrex-
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2.3.5. Implantable Naltrexone Versus Methadone Mainte-
nance 
  Obstetric and neonatal outcomes in a sequential cohort of 
seventeen of the above 43 heroin-dependent pregnant women 
managed by naltrexone implant have been compared with 
ninety women receiving MMT [157]. Following MMT, de-
liveries prior to 37 weeks (24%) and low birthweight (<2500 
g, 23%) were both significantly greater (p<0.001) compared 
to Australian national data for the normal population (deliv-
ery prior to 37 weeks: 5.6%; birthweight<2500 g: 4.6%) 
[317]. By contrast, there was no significant difference be-
tween naltrexone implant-managed women (delivery prior to 
37 weeks: 5.9%; birthweight<2500 g: 11.7%) when com-
pared to National data [157]. In addition, the difficulty of 
adjusting to extra-uterine life for babies born to mothers re-
ceiving MMT was indicated by significantly worse one min-
ute APGAR scores compared to infants of mothers treated 
with a naltrexone implant (p<0.005). However, the lack of 
significance with regards to adverse neonatal effects from 
naltrexone exposure during pregnancy could be a conse-
quence of limited statistical power from the small sample 
size of 17. 
3. ANIMAL STUDIES 
  To appropriately reflect the clinical situation of drug use 
during pregnancy, a number of factors need to be considered 
in animals studies. First, due to interspecies differences in 
pharmacokinetics, delivering a clinically comparable drug 
dosage in animal studies is not simply a case of using rela-
tive dose-to-weight ratio, but requires consideration of blood 
levels, duration of drug retention, and fluctuation from re-
peated dosing. In comparison to humans, where drug fluctua-
tions tend to be minimal and blood levels are maintained 
within the therapeutic range [164], laboratory animals gener-
ally have a much higher rate of drug elimination [278], and 
produce a series of narrow and high-drug concentration 
peaks. Although peak plasma drug concentrations can be 
matched between animals and humans, the duration of clini-
cally relevant blood levels is often harder to control [162, 
164]. Second, the route of administration, and whether it is 
delivered maternally or directly to the offspring, will also 
influence the extent of offspring exposure. Therefore, the 
dose, route of administration, and the total exposure (re-
flected by the area under the concentration-time curve) 
should be assessed [168, 278]. Third, interspecies differences 
in parameters such as the onset, duration and intensity of 
tolerance, withdrawal, stress, and ontogenic response to a 
given dose of drug may also account for differences between 
human and animal offspring development [168, 408, 409].  
  Fourth, the period of exposure during development will 
influence outcome. Different species have different absolute 
developmental timetables. Nevertheless, mammals develop 
to a relative common timetable defined by the caecal period, 
namely the length of time from conception to eye-opening 
[77, 322]. In humans eye-opening occurs during the third 
trimester (182 days), but in rat occurs ~2 weeks after birth 
(gestation = 21 days), i.e. at post-conceptional day 36 days 
[59]. For example, the corpus callosum in rat appears at 18.5 
days post-conception, and in humans appears at 87.5 days 
post-conception, respectively corresponding with 51% and 
48% of the caecal period [59]. Likewise, the end of rapid 
axon loss in the nervous system of rats occurs at day 27 post-
conception, and in humans at 136 days, which both corre-
spond to 75% of the caecal period [77]. 
  Fifth, when using animal models to study the direct, bio-
logical effects of a drug on development, it is desirable to 
control for potential indirect drug effects. For example, dep-
rivation of nutrition has a profound effect on development 
and may result from a number of factors related to drug ex-
posure, such as drug-induced appetite suppression, nutri-
tional value of the milk and maternal behaviour [37, 99, 168, 
408]. Prenatal drug manipulations of pregnant rats can mod-
ify maternal behaviour and so affect developmental parame-
ters in offspring. These include circadian rhythms, milk con-
sumption, activity level, heart rates, oxygen intake and 
growth hormone [168]. The effects can be controlled for 
prenatally by introducing a pair-fed control group, which 
involves matching the food consumption to that of the ex-
perimental group [162]; postnatally, drug-induced maternal 
effects can be isolated by cross-fostering [162], involving 
transfer of offspring from drug treated-mothers to non-
treated mothers, and vice-versa [121]. Furthermore, in ani-
mals which typically birth multiple offspring, a drug may 
affect litter size, which would alter sibling competition with, 
for example, larger litter sizes decreasing nutritional distribu-
tion during gestation and lactation; a small litter size is also 
sub-optimal for offspring nutritional intake as reduced suck-
ling limits maternal milk production and sustenance [173, 
271, 287]. Such effects can be overcome by culling to an 
optimal litter size which in rat, for example, is 8-10 pups. 
3.1. Methadone 
3.1.1. Doses, Metabolism and Transfer 
  In humans, daily oral methadone dosing, combined with 
the long terminal half-life (24 h), avoids withdrawal syn-
drome and results in continuous exposure of the neonate. 
However, in the pregnant rat, methadone metabolism is rapid 
(terminal half-life: 3-5 hours) and once-daily dosing can re-
sult in daily maternal and offspring withdrawal [163]. To 
achieve clinically relevant blood levels (150-500 ng/ml) 
[101, 135] in rats, a daily oral dose of approximately 12.5 
mg/kg is required [166]. However, in most studies (Table 2), 
a daily dose of 5 mg/kg of methadone was administered ma-
ternally, indicating an apparent “under-dosing”. However, 
compared to the clinical situation of oral dosing, intraperito-
neal injections were used which result in high plasma levels, 
as first-pass hepatic metabolism is evaded. Furthermore, 
intraperitoneal injections can result in extraplacental transfer 
directly from the peritoneal cavity to fetal tissues and fluids 
[166, 300], which may account for increased exposure com-
pared to other routes of administration. Nonetheless, in rat, 
methadone crosses the placenta, enters the fetal circulation 
[166] and transfers to the lactate [409]. However, in most 
studies, blood plasma levels were not reported and interspe-
cies differences in the rate of metabolism of methadone 
means that it is hard to replicate fetal plasma exposure found 
in humans [105, 107, 233]. Regardless, ontogenesis in rat is 
affected by a sub-therapeutically relevant dose (5 mg/kg) of 
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3.1.2. Effects on Offspring: Growth and Brain Develop-
ment 
  Decreased birthweights found in humans are consistent 
with animal studies which report that gestational methadone 
exposure reduces growth [99, 166, 256, 410]. An early study 
on maternally administered methadone (10-13 mg/kg/day) in 
primates showed significantly reduced birthweights in the 
offspring [135]. In rat, a number of deleterious effects are 
associated with perinatal methadone exposure including in-
creased mortality of mothers [167] and offspring [34, 166, 
408], as well as low birthweights and growth retardation [41, 
166, 257, 408]. Prenatal methadone also delays the initial 
onset of various physical characteristics in rats, such as the 
appearance of hair and opening of the vagina, eyes and ears 
[103, 253, 383, 412]. 
  The inhibitory growth effects are, to a certain extent 
dose-dependent [41, 166, 420], and influence the animals as 
a whole as well as individual organs, with some being af-
fected more than others [257]. In particular, the central nerv-
ous system (CNS) is a sensitive target [409, 428]. Adverse 
effects include reduced brain size and weight, decreases in 
cell density and total cell number, as well as neurochemical 
alterations (Table 2). In particular, there are consistent de-
creases in protein, DNA, RNA and neurotransmitter content 
(serotonin, dopamine, norepinephrine) [87, 145, 253, 301, 
344], enzymatic protein levels (tyrosine hydroxylase, acetyl-
choline-esterase, choline acetyltransferase, ornithine decar-
boxylase) [87, 224, 327, 338, 342, 343], and receptor expres-
sion (-adrenergic) [66]. Moreover, some of these effects are 
region-specific and age-dependent; for example, norepineph-
rine content has been found to decrease in the forebrain but 
not the hindbrain [253], and whilst acetylcholine-esterase 
levels following prenatal methadone exposure are normal at 
birth, they are reduced at 21-days postnatal [87]. Acetylcho-
line, enkephalin and nerve growth factor are also reduced at 
birth following exposure during pregnancy [123, 319, 366, 
399]. 
3.1.3. Effects on Offspring: Behaviour 
  Methadone during prenatal development affects postnatal 
behaviour. The withdrawal syndrome has been observed in 
Table 2.  Summary of the Effects of Maternally Administered Methadone on the Development of the Rat Brain
Reference 
Daily Dose 
(mg/kg) 
Route of 
Admin. 
Duration of Drug Expo-
sure 
Age of Offspring when 
Evaluated (days) 
Developmental Effects (Compared to Controls) 
[394] 5 s.c.  Gest  1  or  3  Reduced explant outgrowth size. 
[408] 5 i.p. 
Gest-lact or gest-lact + 
post-weaning (60 days) 
0, 3, 6, 10, 15, 21 or 60 
Decreased brain & cerebellar wet weights & reduced
cerebral & cerebellar widths. 
[409] 5 i.p. 
Gest, lact or 
gest-lact 
0, 3, 6, 10, 15, 21 or 60  Decreased cerebellar wet weight & brain length. 
[410] 5 i.p. 
Gest, lact or 
gest-lact 
21 Decreased brain wet weights & DNA content. 
[257] 5 i.p. 
Gest, lact or 
gest-lact 
21
Reduced brain wet & dry weights. 
Smaller head diameters. 
[411] 5 i.p. 
Gest, lact or 
gest-lact 
10, 21 or 60  Decreased brain & cerebellar DNA content. 
[99] 
1-5 (twice 
daily) 
s.c.  Gest day 13 to birth  7, 14, 21 or 28 
Reduction in brain wet weight, cortical thickness & 
the number of cells in the neocortex. 
[256] 5 i.p. 
Gest, lact or 
gest-lact 
60 Decreased head diameter & brain DNA content. 
[418] 5 i.p. 
Gest, lact or 
gest-lact 
21 or 60 
Decreased brain & cerebellar wet weights. Reduced
DNA, RNA & protein concentration in brain & cere-
bellum 
[420] 5 i.p.  Gest  or  lact  21 
Reduced area in the pyramis (cerebellar lobule) & 
decreases in the total number & density of internal 
granule neurons. 
[424]  5  i.p.  Gest-lact 21 Decreased brain wet weight & length. 
[318]  9  s.c. OMP  Gest  4, 10 or 22 
ACh & NGF content reduced in striatal neurons, 
which are smaller in size. 
Gest = gestation, lact = lactation, s.c. = subcutaneous, i.p. = intraperitoneal, OMP = osmotic minipump, ACh = acetylcholine and NGF = nerve growth factor. 136    Current Neuropharmacology, 2008, Vol. 6, No. 2 Farid et al. 
newborn rat offspring following maternal treatment with an 
osmotic minipump throughout pregnancy; NAS was precipi-
tated by a challenge of the opioid antagonist, naltrexone and 
observed as increased motor activity and vocalisation [13]. 
Neonatal abstinence syndrome was also associated with al-
terations in the latency of visually evoked potentials [305]. 
Young and mature adult offspring also displayed increased 
withdrawal-like symptoms in comparison to control animals, 
such as head and body shakes [416].  
  Prenatal exposure to methadone also delayed develop-
ment of reflex and motor coordination [253, 383, 412]. In 
most studies, there was an initial decrease in open field am-
bulation and exploration in rat offspring up to 45 days post-
natal [103, 122, 253, 261, 383, 436]. Conversely, there was a 
consistent increase in open-field activity in rat offspring after 
45 days postnatal [122, 347, 436].  
  Methadone exposure during pregnancy has also been 
found to affect analgesic responses later in life, although the 
effect has been variable; some studies report an increase 
[414, 415, 417, 426] and another a decrease [143, 416]. 
Moreover, the analgesic effects of drugs, such as ampheta-
mine and methadone, were greater in methadone-exposed 
offspring [415, 426]. There was also an increased propensity 
to self-administer oral morphine [144, 261]. Furthermore, 
decreased latency to step down from a platform could indi-
cate increased anxiety [436]. Consistent with human studies, 
memory and learning tests revealed poorer cognitive skills 
[372, 413, 437]. Another study demonstrated that decreased 
discrimination learning was dependent on the period of 
methadone exposure; rats exposed prenatally or postnatally 
displayed an effect, those exposed both pre- and post-natally 
showed none [372]. 
3.2. Buprenorphine  
  Animal studies of the ontogenic effects of buprenorphine 
are relatively limited in comparison to more extensive stud-
ies on the effects of methadone or naltrexone. The pharma-
cokinetics of buprenorphine in pregnant rats is yet to be in-
vestigated.  
3.2.1. Effects on Offspring: Growth and Brain Develop-
ment 
  Maternal exposure to buprenorphine (0.67-2 mg/kg) dur-
ing pregnancy results in an increase in offspring mortality 
within 6 days of birth [83, 320, 366], whilst resorptions were 
unaffected [165]. In contrast to methadone, buprenorphine 
increases the duration of gestation [83]. It is unclear what 
impact prenatal buprenorphine (0.07 or 0.67 mg/kg/day) has 
on birthweight with one study reporting no effect [165], and 
another a decrease [83]. However, prenatal exposure to bu-
prenorphine results in decreased postnatal weight gain [320]. 
  There are more data on biochemical and protein changes 
following prenatal exposure to buprenorphine (Table 3). C-
opioid receptor expression is down-regulated in newborn rat 
offspring [19], but this effect is transient and diminishes by 
postnatal day 7 [20]. Whilst these effects were associated 
with low doses of buprenorphine (0.15-0.5 mg/kg/day), a 
higher dose (2.5 mg/kg/day) resulted in -opioid receptors 
up-regulation in neonatal offspring [19]. In both studies, the 
ligand binding affinities (Kd) for C- and -opioid receptors 
were unaffected. However, in 2-day-old offspring exposed to 
buprenorphine prenatally, receptor function is diminished, as 
evidenced by decreased coupling activity of the stimulatory 
G-protein following agonist stimulation of C- (ventral teg-
mental area) and N/OFQ-opioid receptors (lateral septum 
and nucleus accumbens), [141]. The decline in receptor ac-
tivity was transient, diminishing by postnatal day 7, and a 
gender related difference was reported, with males having 
greater decreases in receptor function.  
  Prenatal buprenorphine exposure also results in a de-
crease in choline acetyltransferase mRNA in postnatal off-
spring [318] although striatal mRNA levels for the C-, - and 
-opioid receptors are unaffected [19, 366]. Administration 
of 0.3 mg/kg of buprenorphine during gestation resulted in a 
decrease of striatal acetylcholine content in 4 day old rat 
offspring, although there was an overshoot with greater lev-
els than controls at 21 days [319]. However, treatment with a 
higher dose (3 mg/kg) decreased striatal acetylcholine con-
tent in both 4- and 21-day-old rat offspring. Prenatal bu-
prenorphine does not affect NGF mRNA levels in postnatal 
day 10 [318] although striatal NGF content was decreased 
[318, 321].  
  The effects of postnatal exposure have also been investi-
gated, but the studies are few and did not show significant 
effects [165, 169]. Due to the mixed agonist-antagonist ac-
tion of buprenorphine, translation of its mechanism of action 
has been limited because of the following: 1) the pharma-
cokinetics of buprenorphine in the pregnant rat, or any other 
animal, does not appear to have been evaluated; 2) the onto-
genic role of the -opioid receptor requires clarification, as 
does the pharmacological action of buprenorphine at this 
receptor; and 3) levels change during each 24 hour cycle of a 
daily dosing regime; initial high doses result in antagonism 
at the C-opioid receptor and later low doses result in agonist 
action. Presumably, during each 24 hour period, the devel-
opmental effects would alternate as blood levels fluctuate. 
Avoidance of fluctuating levels using constant infusion may 
help to separate the agonist/antagonist effects of buprenor-
phine. However, such studies would be difficult during laca-
tion because maternal delivery via the milk would also fluc-
tuate; furthermore, constant infusion in neonatal rats is diffi-
cult. Differential impact on receptor expression has been 
demonstrated with up-regulation of - and -opioid receptors 
and down-regulation of -opioid receptors from daily intrap-
eritoneal injections >0.5 mg/kg during the postnatal period 
[18]. Gestational exposure was shown to have similar effect 
on - and -opioid receptors, when evaluated at the time of 
birth [19]. These effects are similar to that expected from 
methadone at C-opioid receptors, although with less efficacy, 
and similar to naltrexone at the kappa-opioid receptor. It is 
unknown what effect buprenorphine has on the -opioid re-
ceptor; considering the significance of this receptor’s role in 
ontogenesis, this warrants further investigation.  
3.2.2. Effects on Offspring: Behaviour 
  Following buprenorphine exposure, a number of behav-
ioural changes are detected including decreased sensitivity to 
morphine, increased morphine-withdrawal and an earlier 
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[320]. A gender-related difference in preference for saccha-
rine is diminished following offspring exposure to prenatal 
buprenorphine [14], although rest-activity was unaffected 
[165]. The effects could be explained by parental behaviour 
(i.e. pup retrieval, grooming and hovering/crouching over the 
pups), being impaired during the prenatal or postnatal period 
[14]. 
3.3. Naltrexone  
  While the initial clinical data may appear to provide 
some evidence that outcomes associated with both implant 
Table 3.  Summary of the Effects of Maternally Administered Buprenorphine on the Development of the Rat Brain 
Ref-
erence 
Daily Dose 
(mg/kg) 
Route of 
Admin. 
Duration of Drug 
Exposure 
Age of Offspring when 
Evaluated (days) 
Developmental Effects (Compared to Controls) 
[366]  1 or 2  s.c.  Gest  21  No effect on met- or leu-enkephalin levels. 
1 Decreased B-receptor Bmax in  
brain membranes. 
7 No effect on B-receptor Bmax in  
brain membranes. 
[17] 0.5  i.p.  E14-22 
1 & 7  No effect on B-receptor Kd. 
[165]  0.3, 1 or 3  s.c. OMP  E8-E22  0, 22 or 30  No effect on rest-activity cycle. 
[14]  0.15 or 0.3  s.c.  E6-20  1, 28, 50 
Impaired parental behaviour (0.6), expected sex difference for 
saccharine preference diminished (males consuming more in 
0.6 grp). 
2.5  Up-regulation of -receptors. 
[19] 
0.15, 0.3 or 
2.5 
s.c. E6-20  1 
Down-regulation of B-receptor.  
No effect on B- nor -receptor Kd & mRNA. 
[321] 1.5 s.c.  OMP 
E7-22, P0-10 & E7-
P10 
10 Decreased striatal NGF content by >40%. 
[318]  -  -  Gest  10 & 22  Decreased striatal choline acetyltransferase mRNA. 
[320]  0.3, 1 or 3  s.c. OMP  E7-P13, P0-13 or 
E7-P13 
0-21 
Increase in morphine ED25 pre &/or post (larger dose=large 
decrease in sensitivity). 
Increased withdrawal score (0.3 & 3).  
Altered timing of behavioural characteristics. 
10 Decreased striatal NGF. 
[399] 1.5 s.c.  OMP  E7-P0, P0-10 or E7-
P10  4 or 10  No effect on NGF mRNA. 
E7-P0 4    Decreased striatal ACh. 
E7-P0 
0.3 
P0-21 
21 Increased striatal ACh (males). 
P0-21 4 
[319] 
3
s.c. OMP 
E7-P21 21 
Decreased striatal ACh. 
2 Decreased B-receptor GTPS binding in  
ventral tegmental area. 
0.5 or 1 
7 No effect on B- nor N/OFQ-receptor  
GTPS binding.  [141] 
1
s.c. OMP  E10-P7 
2
Increased N/OFQ-receptor GTPS binding in nucleus accum-
bens & lateral septum (males). 
Gest = gestation, E = embryonic day, P = postnatal day, s.c. = subcutaneous, i.p. = intraperitoneal, OMP = osmotic minipump, ACh = acetylcholine, NGF = nerve growth factor and 
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and oral naltrexone may be as good, if not better, than ob-
served with methadone, research data from animal work 
raises concern. 
3.3.1. Doses, Metabolism and Transfer 
  In rat, naltrexone is metabolised to 6,-naltrexol and the 
minor metabolites via the same metabolic pathways [380]. 
The elimination half-life is 4.6 hours [402] being very simi-
lar to human (4 h). However, relative to naltrexone, small 
amounts of 6,-naltrexol are found in rat plasma and urine, 
whereas significant quantities are found in humans [240]. 
Notwithstanding the difference, naltrexone-plasma levels of 
2 ng/ml in rat have been shown to block the analgesic effects 
of morphine (plasma concentration: >1000 ng/ml) [402], 
which parallels the pharmacodynamic efficacy of naltrexone 
in humans [15, 181].  
  Most experiments used high doses of naltrexone (50 
mg/kg/day) that are above those used clinically and may, 
therefore, be misleading. Naltrexone levels which affect de-
velopment are reportedly small (0.05-2.5% of the LD50 in 
adult rats) [428]. With an LD50 of approximately 2000 mg/kg 
in adult rats [31, 439], the dosages required to induce and 
effect in rats are 1-50 mg/kg, with 1 mg/kg considered a low 
dose (Table 5), and 50 mg/kg a high dose (Table 4) [425].  
  Naltrexone transfer across the placenta has been estab-
lished in rats [406, 407]. Naltrexone has not yet been meas-
ured in rat lactate. However, since naltrexone transfer to milk 
has been confirmed in humans and sheep, it is presumed that 
transfer into rat milk will also occur. Indeed, naltrexone has 
been detected in the blood of 4-week-old offspring when 
naltrexone was only delivered maternally
1, suggesting that it 
is indeed transferred to the rat lactate and can therefore affect 
development after birth [39, 40]. 
3.3.2. Effects on Offspring: Growth and Brain Develop-
ment 
  The effects of naltrexone on growth are somewhat oppo-
site to the suppression following prenatal exposure to metha-
                                                
1 Farid, W.O., Tait, R.J., Hulse, G.K., Dunlop, S.A. (2006) The effects of maternally 
administered methadone and naltrexone on the developing brain (Poster Abstract). 
Proceedings of the Australian Neuroscience Society: 26th Annual Meeting, 17, 76. 
Table 4.  Summary of the Effects of High/Continuous Doses of Naltrexone on Postnatal Development of the Rat Brain when Ad-
ministered Directly (with One Exception of Maternal Administration) 
Reference 
Daily Dose 
(mg/kg) 
Route of 
Admin. 
Duration of Drug 
Exposure 
Age of Offspring when 
Evaluated (days) 
Developmental Effects (Compared to Controls) 
[422] 50  s.c. 
Birth until 21 days
postnatal 
21
Greater brain & cerebellar wet weights. Thicker
somatosensory cortex. Cerebellum total area larger.
More glial cells & granule neurons. 
[423] 50  s.c. 
Birth until 21 days
postnatal 
21 Increased brain wet weight. 
[425] 
3 (3 times 
daily), 20, 50 or 
100
s.c. 
Birth until 21 days
postnatal 
21 Increased brain wet weight. 
[428] 50  s.c. 
Birth until 21 days
postnatal 
21 Increased brain wet & dry weights. 
[429] 50  s.c. 
Birth until 21 days
postnatal 
21
Increase in number of granule cells of dentate gyrus.
Increase in cerebral & cortical width & area. 
[430] 50  s.c. 
Birth until 21 days
postnatal 
21
Increases in cerebellar surface dimensions, neural 
cell numbers, density & size. 
[431] 50  s.c. 
Once on postnatal 
day 6 
6
Increased proliferation 
(labeling index) in cerebellum. 
Birth until 10 days
postnatal 
10
Increased purkinje cell dendritic length & spine 
concentration of granule cells.  [133] & 
[134] 
50 s.c. 
Birth until 21 days
postnatal 
21
Increased cell dendritic length & spine concentra-
tion in hippocampus. 
[174] 50  i.p. 
Once on postnatal 
day 1 
1
Increased proliferation (labelling index) in ganglion
cell layer of the retina 
[254] 50 
Maternal 
i.p. 
Daily throughout 
gestation 
0, 10 & 21  Increased brain dry & wet weights. 
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done and other opioids [161, 223, 345, 421]. A number of 
studies indicate increased body weight and length and also 
increased dry and wet weights of body organs including the 
brain [254, 255, 442]. However, an increased level of com-
plexity is that the effects of naltrexone on growth can be 
either stimulatory or inhibitory depending on the dose and its 
duration [423, 425, 428, 430], a scenario that is likely in the 
clinical setting. However, in these studies, blood plasma 
concentrations were not measured and have to be inferred 
from the dose regime. For example, in rat, daily administra-
tion of a high dose (50 mg/kg) of naltrexone, ensures con-
tinuous blockade of receptors and results in accelerated 
growth (Table 4). In contrast, daily administration of a low 
dose (1 mg/kg) blocks receptors temporarily because the 
agent is eliminated before dosing the next day; this intermit-
tent blockade has been associated with inhibition of growth 
(Table 5). The inhibitory effect is similar to that seen follow-
ing developmental exposure to an opioid agonist, such as 
morphine or methadone [431]. However, some studies adher-
ing to similar dosing regimens report no effect [64, 137, 
302], a discrepancy which has yet to be clarified. 
  Nevertheless, the duration of opioid receptor blockade 
appears to be more important in modulating development 
rather than its actual dose [425]. Multiple doses of naltrex-
one (3 mg/kg three times per day), which ensure continuous 
receptor blockade, accelerates body and brain development. 
By contrast, a single cumulatively equivalent dose (9 mg/kg 
once per day), which induces intermittent receptor blockade, 
has an inhibitory effect [425].  
  Intermittent blockade by antagonists can exert its effects 
via a mechanism termed supersensitivity, which is character-
ised by accentuation in receptor expression and function [17, 
335, 428]. In the absence of activation, alterations in receptor 
structure can result in a change to a high agonist affinity state 
[309, 445]. In the high affinity state, a dose which previously 
elicited a response of a particular magnitude may induce a 
response of a much greater magnitude due to the higher inci-
dence of binding and subsequent receptor activation. An 
increase in the number of opioid receptor binding sites also 
contributes to a higher incidence of binding and hence, su-
persensitivity to opioids [423, 428, 431]. Supersensitivity 
can also be associated with increased endogenous agonist 
levels and/or increased affinity, and/or efficacy of the recep-
tor-agonist complex. Indeed, opioid antagonists are also 
known to increase the levels of endogenous opioids, such as 
-endorphin [429]. Thus, compared to normal, in a supersen-
sitive state, basal or elevated endogenous opioid levels can 
exert a greater inhibitory action, manifested by a reduced 
rate of cell proliferation and growth [428]. 
  Experimental studies have yet to investigate the devel-
opmental effects of naltrexone delivered as a sustained-
release implant or depot. GoMedical implants release ap-
proximately 220 <g/kg/day in humans and achieve plasma 
levels of 2-10 ng/ml [147-149]. The amount released is 4-5 
times lower than the minimum dose that is thought to affect 
development and it is not yet known whether naltrexone de-
livered in this way will have an effect, an issue that warrants 
investigation. Nevertheless, one study showed that continu-
Table 5.  Summary of the Effects of Low/Intermittent Doses of Naltrexone on Postnatal Development of the Rat Brain when Ad-
ministered Directly 
Reference 
Daily Dose 
(mg/kg) 
Route of 
Admin. 
Duration of Drug 
Exposure 
Age of Offspring when 
Evaluated (days) 
Developmental Effects (Compared to Controls) 
[423] 1 s.c. 
Birth until 21 days 
postnatal 
21 Decreased brain wet weight. 
[425]  0.1, 1 or 9  s.c. 
Birth until 21 days 
postnatal 
21 Decreased brain wet weight. 
[428] 1 s.c. 
Birth until 21 days 
postnatal 
21 Decreased brain wet & dry weights. 
[429] 1 s.c. 
Birth until 21 days 
postnatal 
21
Increase in cell density, with decreased macroscopic 
area of hippocampus.  
Decreased cerebral area & width. 
[430] 1 s.c. 
Birth until 21 days 
postnatal 
21
Decreases in cerebellar surface dimensions & density 
of internal granule cells. 
[431] 1 s.c. 
Once on postnatal 
day 6 
6 Decreased proliferation (labeling index) in cerebellum.
[134] 1 s.c. 
Birth until 10 or 21 
days postnatal 
10 or 21 
Subnormal dendrite length & spine growth, predomi-
nant by day 21. 
Admin. = administration, s.c. = subcutaneous, and i.p. = intraperitoneal. 140    Current Neuropharmacology, 2008, Vol. 6, No. 2 Farid et al. 
ous naltrexone exposure (10 mg/kg/day via osmotic mini-
pump) during the pre- and post-natal period resulted in in-
creased thickness of the cerebral cortex and decreased, pack-
ing density although cortical cell number remained the same 
[337]. In contrast to accelerated growth from continuous 
prenatal exposure, it is hypothesised that, during the postna-
tal period, a maternally administered sustained-release nal-
trexone implant will do the opposite compared to intrauterine 
exposure, i.e. offspring will be exposed intermittently during 
feeding from the mother. Furthermore, as tolerance is not 
observed with naltrexone exposure [204, 266, 376], it is hy-
pothesised that the resulting developmental effects would be 
influenced by the developmental phase taking place during 
exposure with differential opioid receptor expression playing 
a crucial role [11, 132]. 
  Whilst developmental studies on naltrexone’s effect on 
neurochemistry are sparse, daily injections (50 mg/kg) of rat 
pups had variable effects on NGF, with decreases in cerebel-
lum and increases in the hippocampus [268]. Exposure to 1 
mg/kg also decreased NGF content in hippocampus, septum 
and neostriatum whereas 50 mg/kg had no effect on NGF 
content but decreased the number of NGF high affinity bind-
ing sites [298]. A lower dose (1 mg/kg) administered to pups 
from birth until day 21 decreased striatal and hippocampal 
serotonin levels in adulthood [379], following an increase in 
striatal serotonin at 22 days postnatal [63]. 
3.3.3. Effects on Offspring: Behaviour  
  Behavioural differences are manifested at the cellular 
level by alterations in excitability and changes in the mor-
phology and connectivity [348]. Daily injections into preg-
nant rats result in changed behaviour of offspring after birth, 
for example, decreased grooming, ambulation and defecation 
[254, 255, 442]. The effects of gestational and/or postnatal 
exposure to naltrexone on behaviour have been explored [8, 
48, 65, 131, 202, 255, 258, 297, 427, 438]. Daily exposure to 
50 mg/kg during the pre-weaning period accelerates the de-
velopment of spontaneous motor and sensorimotor behav-
iours, namely initial appearance and the age at which 100% 
of the animals demonstrate a particular behaviour [255]. In 
contrast, daily exposure to 1 mg/kg delayed the initiation of 
developmental events such as ear opening, eye opening and 
walking. Whilst control and 1 mg/kg naltrexone groups are 
comparable in motor activity at 21 days, an increase of 32% 
in activity was recorded in animals of the 50 mg/kg group 
[427]. Mice administered with 10 mg/kg twice daily through-
out gestation and lactation reared offspring who displayed 
increased locomotor activity in adulthood [258]. 
  Naltrexone exposure during gestation and the post-
weaning period decreased the sensitivity of the offspring to 
the analgesic effects of morphine [131, 297, 438]. Only one 
study has examined the behavioural effects of sustained-
release naltrexone (via a minipump; 10 mg/kg/day), starting 
on day 17 of gestation [202]. As prenatal stress was included 
as a treatment in this paradigm, only a few independent ef-
fects of naltrexone on the offspring were identified. These 
included increased anxiety, decreased preference for saccha-
rin and decreased sensitivity to pain. Increased anxiety and 
emotionality was found in another study exploring condi-
tioned emotional response, although exposure to naltrexone 
was via daily maternal administration of 1 mg/kg throughout 
gestation [131]. Other behavioural effects of naltrexone ex-
posure during development include facilitation of male sex 
behaviour as indicated by a shorter mount time [48], and 
reduced food intake after 14 days of postnatal exposure [8]. 
Another study in sheep showed that acute naltrexone admini-
stration (1.5 or 3 mg/kg, intrapeitoneal) within 24 hours of 
birth prevented lambs from recognising their mother, sug-
gesting an interruption of bonding via the opioid reward sys-
tem [340]. 
CONCLUSIONS 
  Studies in humans to date have shown that MMT during 
pregnancy is associated with a number of adverse neonatal 
effects, including reduced birth-weight and the incidence of 
NAS. However, the negative outcomes associated with 
MMT outweigh the detrimental effects associated with her-
oin use during pregnancy, although whether these benefits 
are due to MMT or to improved psychosocial stability needs 
clarification through well-controlled randomised trials. There 
are an abundance of data from animal pregnancy studies that 
reflect many of the adverse effects seen in humans, many of 
which have involved clinically applicable dosing regimens. 
However, various aspects of MMT, such as the potential 
benefits of split-dosing and breast feeding to treat NAS have 
received little attention in animal research and warrant eluci-
dation.  
  Buprenorphine has arisen more recently as an alternative 
treatment for the pregnant addict and there is evidence to 
suggest a number of advantages over MMT, such as a re-
duced incidence and severity of NAS. However, both human 
and animal data are limited. Moreover, notwithstanding the 
complexity of interpreting the developmental effects of a 
partial agonist, both human and animal studies have high-
lighted detrimental neonatal outcomes. In particular, the dif-
ferential pharmacological activity, which is dependent upon 
dose, needs to be investigated in terms of ontogeny, to de-
termine which regimen offers optimal outcomes for the new-
born. 
  An even more novel approach for treating the pregnant 
heroin user, using naltrexone, offers the advantage of evad-
ing withdrawal in the newborn and is accounted for by its 
lack of agonist activity. The advent of administering naltrex-
one as a sustained-release implantable preparation has re-
sulted in an increase in the frequency of inadvertent exposure 
of the neonate to naltrexone. Nonetheless, based on human 
data, this mode of delivery is promising as early indications 
suggest an absence of detrimental neonatal outcomes, al-
though the work urgently requires validation. Moreover, 
animal research, examining oral or injected naltrexone, has 
demonstrated that the developing neonate is affected follow-
ing gestational exposure. The sustained-release implant de-
scribed for use in humans results in chronic and low-dose 
exposure, a regimen which has yet to be applied in animal 
studies. Since animal studies using other dosing regimens 
raise concern, research on the sustained-release preparation 
is also necessary. 
  Pregnancy remains a unique situation where very impor-
tant and considerable ethical judgment is required when The Effects of Maternally Administered  Current Neuropharmacology, 2008, Vol. 6, No. 2    141
commenting on pharmacological treatment and more animal 
data should be made available to determine which pharma-
cotherapy provides the optimal neonatal outcomes. Given the 
detrimental impact of illicit drug use during pregnancy, in-
vestigation of pharmacological treatment during pregnancy 
is very important, urgently needed and appropriate further 
investigation should be undertaken. 
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